Digest Network Come funziona
Network
/
Società
No
Non verificato

Novartis Pharma AG

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

89 comunicati stampa

Guarda tutti i comunicati
08/04/2026
Farmaceutica
Annunci Economici
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
28/03/2026
Farmaceutica
Annunci Economici
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
26/03/2026
Farmaceutica
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
22/03/2026
Farmaceutica
Annunci Economici
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
19/03/2026
Farmaceutica
Annunci Economici
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
13/03/2026
Farmaceutica
Annunci Economici
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
06/03/2026
Farmaceutica
Annunci Economici
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
27/02/2026
Farmaceutica
Annunci Economici
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
27/02/2026
Farmaceutica
Annunci Economici
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
25/02/2026
Farmaceutica
Annunci Economici
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0